Grayanotoxin: the active compound in mad honey

Introducing the molecule

Grayanotoxin is the name given to a family of structurally related diterpenoid compounds isolated from plants in the Ericaceae family — most prominently the genus Rhododendron. The compound was first characterized in 1834 when Procter isolated a crystalline compound from Rhododendron maximum; it was then called "andromedotoxin" after Andromeda polifolia, another Ericaceae plant containing the same class of molecule. The modern name "grayanotoxin" comes from the type compound being isolated from Leucothoe grayana. Older literature uses the names interchangeably.

Grayanotoxin is what makes mad honey "mad." Every effect — the bradycardia, the vasodilation, the tingling, the warmth, the drowsiness, and at high doses the syncope and AV block — traces back to this single class of compound binding a single molecular target.

Chemical structure

Grayanotoxin is a tetracyclic diterpene. Its skeleton consists of four fused carbon rings (A/B/C/D in conventional nomenclature) with several hydroxyl substitutions that vary between the isoforms. The molecule is moderately lipophilic, which is why it crosses biological membranes (including the blood–brain barrier and the placenta) readily.

Molecular formula for grayanotoxin I: C₂₀H₃₆O₅. Molecular weight approximately 412 Da.

The three dominant isoforms in Rhododendron nectar are:

• Grayanotoxin I — dominant in R. arboreum (the main Nepalese source), most potent.
• Grayanotoxin II — minor constituent across species.
• Grayanotoxin III — dominant in R. ponticum (the main Turkish source), slightly less potent per molecule than I.

These are not the only grayanotoxins — over 60 structurally related compounds have been characterized from Ericaceae — but they are the dominant ones in mad honey.

The mechanism: voltage-gated sodium channels

Grayanotoxin's pharmacology is extremely specific at the receptor level. It binds to site 2 of the alpha-subunit of voltage-gated sodium channels (Na_v). These channels are integral membrane proteins that open in response to membrane depolarization, allow sodium influx into the cell, and then close (inactivate) after a few milliseconds. This cycle is the basis of the action potential — the electrical signal that propagates along nerve fibers and triggers muscle contractions, including cardiac conduction.

When grayanotoxin binds site 2, the channel cannot inactivate normally. Sodium continues to flow through. The result is sustained depolarization of the membrane. In nerve tissue this produces altered nerve firing — both excitation and later suppression depending on the cell type. In cardiac tissue, sustained depolarization produces the characteristic slowed sinus rate and prolonged AV conduction that define mad-honey cardiovascular effects.

The same mechanism is exploited by several other natural-product sodium-channel toxins — batrachotoxin (poison dart frog), veratridine (Veratrum), and aconitine (Aconitum) — though those are far more potent and far more toxic than grayanotoxin.

Na_v subtype selectivity

Not all voltage-gated sodium channels are the same. The human genome encodes nine subtypes (Na_v1.1 through Na_v1.9) with different tissue distributions. Grayanotoxin binds most subtypes but with varying affinity:

• Na_v1.5 (cardiac) — high affinity, producing the bradycardia and conduction-slowing effects.
• Na_v1.7 (peripheral sensory neurons) — moderate affinity, producing the tingling sensation.
• Na_v1.2 (CNS) — moderate affinity, contributing to central effects.

The cardiac effect is dominant clinically because cardiac conduction is intolerant of subtle disruption in a way that, say, skin sensation isn't.

Pharmacokinetics

Covered in depth in our pharmacokinetics blog post. Summary:

• Absorption: Oral; 30–90 min to first effect.
• Distribution: Lipophilic, crosses blood–brain barrier and placenta.
• Metabolism: Hepatic, primarily CYP3A4 + CYP2C9.
• Elimination: Mostly biliary/fecal post-metabolism. Minor urinary component.
• Half-life: Estimated 8–12 hours from symptom-resolution data (no direct human PK study).

Concentration across plants

Not all Rhododendrons produce grayanotoxin-rich nectar. The content varies by species, individual plant genetics, soil composition, and growing conditions. High-content species include:

• Rhododendron ponticum (Turkey, Caucasus) — dominant in deli bal.
• Rhododendron luteum (Turkey, Caucasus) — yellow azalea, contributory.
• Rhododendron arboreum (Nepal, Himalayan India) — dominant in Nepalese mad honey.
• Rhododendron campanulatum (high-altitude Himalaya) — high-potency at altitude.
• Rhododendron grande (Bhutan, Sikkim) — Bhutanese source.

Garden hybrids and many ornamental rhododendrons produce grayanotoxin too, but typically at lower concentrations and from plants not in dense-enough stands to dominate bee foraging. Our rhododendron pillar covers the botany in detail.

Clinical toxicology

At therapeutic-equivalent doses (1–5 g Nepalese honey), grayanotoxin produces mild physiological effects. At higher doses it crosses into clinical toxicology territory:

• Mild: Bradycardia, hypotension, mild CNS depression.
• Moderate: Symptomatic bradycardia, orthostatic hypotension, nausea.
• Severe: High-grade AV block, syncope, shock — rare.

The lethal dose in humans is not well-characterized because fatality is exceedingly rare. Animal studies suggest LD₅₀ values that would require dozens of grams of pure toxin-concentrated honey — far above any practical exposure. Documented human fatalities are almost exclusively in patients with pre-existing severe cardiac disease or in massive-overdose circumstances.

Detection and assay methods

Grayanotoxin is detected in honey through several methods:

• Melissopalynology: Pollen microscopy identifies Rhododendron pollen as a proxy for grayanotoxin content.
• LC-MS: Liquid chromatography with mass spectrometry gives direct quantitative grayanotoxin measurement.
• GC-MS: Gas chromatography with mass spec, older method.
• Bioassay: Historically used cardiac-preparation tests. Not standard practice now.

Reputable mad-honey brands publish either pollen analysis (pollen % as a proxy) or direct grayanotoxin quantification per batch. Our authentication pillar covers how to read these reports.

Grayanotoxin outside mad honey

Grayanotoxin isn't unique to mad honey. It occurs in several other ethnobotanical contexts:

• Kalmia latifolia (mountain laurel) — eastern US native, occasionally produces toxic honey.
• Lyonia and Pieris species — Japanese honey historically associated with toxicity.
• Rhododendron leaves — historically used in traditional medicine preparations, often with significant toxicity risk.
• Ericaceae-contaminated agricultural honey — rare but documented in some temperate agricultural regions where Rhododendron is invasive.

Historical science

The scientific characterization of grayanotoxin has a 190-year history. Procter (1834) isolated andromedotoxin. Plugge (1881) and Eykman (1883) extended the work on Japanese honey toxins. Moore and Wakeman (1931) established the structural relationship between grayanotoxin isoforms. Seyama et al. (1982) characterized the voltage-gated sodium channel mechanism. Modern understanding of site-2 binding kinetics dates from the 1990s–2000s.

Therapeutic potential

Research on grayanotoxin as a potential therapeutic agent is sparse but not non-existent. The compound's specific sodium-channel binding has been explored as a pharmacological tool for studying channel inactivation kinetics. Potential therapeutic applications — mild antihypertensive, peripheral analgesic — have not progressed beyond early-stage research because synthetic modifications of the core structure have not produced candidates with favorable therapeutic index.

Bottom line

Grayanotoxin is a specific, well-characterized family of plant-derived sodium-channel modulators. One mechanism explains every clinical effect of mad honey. Understanding this molecule — its binding, its pharmacokinetics, its isoforms — is the foundation of understanding everything mad honey does. For deeper reading see our pharmacokinetics post, cardiac effects post, and dose-response post.